摘要
目的探讨氨氯地平与尼群地平分组门诊治疗高血压的疗效。方法抽取2015年4月—2017年7月160例高血压患者,运用随机数字表法将其分为对照组(n=80)与实验组(n=80),对照组患者予以尼群地平的方法治疗,实验组患者予以氨氯地平的方法治疗,观察两组患者治疗前后的血压变化情况、不良反应的发生情况与心绞痛发作例数。结果治疗前,两组患者的血压水平无显著差异,不具有统计学意义(P>0.05);治疗后,实验组的收缩压、舒张压、不良反应的总发生率分别为(121.25±5.01)mm Hg、(79.26±6.19)mm Hg与2.50%,对照组的收缩压、舒张压、不良反应的总发生率分别为(139.34±4.28)mm Hg、(86.39±6.91)mm Hg与12.50%;治疗1个月与3个月后的心绞痛发作例数明显低于对照组,二者差异具有统计学意义(P<0.05)。结论氨氯地平能够有效的治疗高血压,不仅能够使患者的血压接近正常值,而且能够有效的降低不良反应的发生率,并且能够防止心绞痛的发作,具有较高的可行性与临床推广价值。
Objective To investigate the effect of amlodipine andnitrendipine in outpatient treatment of hypertension. Methods A total of160 hypertensive patients from April 2015 to July 2017 were selectedand divided into control group (n = 80) and experimental group (n = 80)by random number table. Patients in the control group were treated withnitrendipine. The patients in the experimental group were treated withamlodipine. The changes of blood pressure before and after treatment,the incidence of adverse reactions and the number of angina pectoriscases were observed. Results Before treatment, there was no signifcantdifference in blood pressure between the two groups (P 〉 0.05). Aftertreatment, the overall incidence of systolic blood pressure, diastolicblood pressure and adverse reactions of the experimental group were(121.25±5.01 ) mmHg , (79.26±6.19) mmHg and 2.50% respectively.The total incidences of systolic blood pressure, diastolic blood pressureand adverse reactions of the control group were (139.34±4.28) mmHgand (86.39±6.91) mmHg and 12.50% The incidence of angina pectorisin one month and three months was significantly lower than that incontrol group, with significant difference (P 〈 0.05). ConclusionAmlodipine can effectively treat high blood pressure, not only can makethe patient's blood pressure close to normal, but also can effectivelyreduce the incidence of adverse reactions, and can prevent the onset of angina pectoris, with high feasibility and clinical value.
出处
《中国卫生标准管理》
2017年第28期116-118,共3页
China Health Standard Management
关键词
高血压
氨氯地平
尼群地平
可行性
hypertension
Amlodipine
Nitrendipine
feasibility